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Since the discovery that nitric oxide ('NO) accounts for the biologic activity of endothelial-derived
relaxing factor, a torrent of research over the last decade has focused on its role, protective or
detrimental, in myriad pathophysiologic conditions. Recently, increasing attention has focused on
'NO as a possible mediator of the severe hypotension and impaired vasoreactivity characteristic
of circulatory failure. Given the ubiquitous and complex role of 'NO in biologic systems, inhibition
of 'NO synthesis in experimental and clinical studies of shock has yielded mixed, sometimes
contradictory, results. Although overproduction of 'NO in the vasculature may result in systemic
vasodilatation, 'NO synthesis has also clearly been shown to have a beneficial role in regulating
organ perfusion and mediating cytotoxicity. In this review, the pathophysiologic importance of
'NO in septic shock and hemorrhagic shock is discussed, and novel therapeutic strategies for
manipulation of 'NO formation are examined. - Environ Health Perspect 106(Suppl 5):
1139-1143 (1998). http://ehpnetl.niehs.nih.gov/docs/1998/Suppl-5/1139-1 143shah/abstract.html
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Introduction
Since the first report that nitric oxide
(*NO) can account for the biologic activity
of endothelial-derived relaxing factor,
increasing evidence has accumulated over
the last decade that NO plays an impor-
tant role in various biologic systems (1,2).
*NO is formed from the amino acid
L-arginine via the enzyme nitric oxide syn-
thase (NOS). Three distinct isoforms of
NOS are known to exist; two were origi-
nally described as constitutive and one
inducible (3). The constitutive enzymes,
neuronal NOS (nNOS or NOS1) and
endothelial NOS (eNOS or NOS3) are
primarily calcium-calmodulin dependent,
although eNOS does exhibit calcium-
independent activity under certain condi-
tions. The inducible NOS (iNOS or
NOS2) is fully active at physiologic
calcium levels. When stimulated, nNOS
and eNOS intermittently produce small
(picomolar) amounts of NO over short
time intervals. Their main function is as
cell-signaling mediators of physiologic
processes such as neurotransmission, regu-
lation oflocal blood flow, and blood pres-
sure. In contrast, iNOS generates large
(micromolar) quantities of NO over
extended periods of time during host
defense and immunologic reactions (3,4).
Though typically absent in resting cells,
iNOS induction has been shown to occur
in response to immunologic stimuli such as
cytokines and microbial products, and in
response to hypoxia (5). This upregulation
ofiNOS has been demonstrated in myriad
cells, exerting either a cytoprotective or
cytotoxic effect (4). However, vascular
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smooth cells can also express iNOS, as can
the endothelium, leading to overproduc-
tion of NO in the circulation (6).
Intense recent research has focused on
NO as a possible mediator ofthe charac-
teristic hemodynamic features of circula-
tory failure (7,8). Indeed, several
experimental and clinical studies have
suggested NOS inhibition might have
therapeutic potential in circulatory shock,
and other studies have clearly demon-
strated the beneficial nature of iNOS
expression in modulating tissue perfusion
and mediating cytotoxicity (9,10). In this
review, we discuss the pathophysiologic
importance of iNOS expression in circu-
latory shock and also examine novel ther-
apeutic strategies for manipulation of
NO formation.
Role of NO in Sepsis
The possible involvement ofthe L-arginine-
NO pathway in both the vascular and
cellular processes seen in sepsis has been
supported by numerous in vitro and
in vivo studies (4). iNOS appears to be
expressed in a wide array of cell types
during sepsis, including immune cells
(such as macrophages, neutrophils, T
lymphocytes), as well as cells outside the
classical immune system (for example,
hepatocytes, Kuppfer cells, vascular
smooth muscle cells, endothelial cells, and
fibroblasts). Expression of iNOS is regu-
lated, both positively and negatively, by a
number ofmediators present during infec-
tion and inflammation. The main stimuli
for iNOS induction indude lipopolysaccha-
ride (LPS), interferon-y, interleukin (IL)-
10, and tumor necrosis factor (TNF)-a;
inhibitory cytokines, such as transforming
growth factor-5, IL-4 and IL-10, as well as
glucocorticoids, can prevent this induc-
tion. The expression ofiNOS in response
to these agents differs among cell types,
but a maximal inducing effect is generally
obtained by the combination ofmicrobial
products and cytokines acting synergisti-
cally (4). iNOS activity is also regulated
by substrate and cofactor availability.
Tetrahydrobiopterin (BH4), an essential
cofactor for the enzyme, is coinduced with
iNOS in cytokine-stimulated vascular
smooth muscle cells (11).
Although NO is a simple molecule, its
widespread production in sepsis, coupled
with its effects on a variety of intracellular
and extracellular target molecules, results in
a complex array ofbiologic roles (10). The
Environmental Health Perspectives * Vol 106, Supplement 5 * October 1998 1139SHAH AND BILLIAR
interaction of NO with the metalloproteins
in a number ofkey enzymes can modulate
their activity. Many of the signaling
actions of 'NO are mediated by soluble
guanylate cyclase. By binding the iron on
the heme component ofsoluble guanylate
cyclase, NO is able to activate the enzyme
leading to cyclic guanosine monophos-
phate (cGMP) formation. Increased
cGMP levels account for several of the
important cellular actions of NO, includ-
ing smooth muscle relaxation, platelet
aggregation and adherence, as well as neu-
trophil chemotaxis. However, through its
disruption ofiron-sulfur clusters in essen-
tial energy-generating enzymes involved
in mitochondrial electron transport, gly-
colysis, and the Krebs cycle, *NO can
adversely affect cellular metabolism.
Furthermore, high concentrations of NO,
as produced by induced macrophages, can
directly interfere with DNA in target cells,
resulting in fragmentation. A combination
of these effects is thought to account for
the cytotoxic role of NO against micro-
bial proliferation during infection (10,12).
Another critical reaction that 'NO under-
goes during inflammation is with the
superoxide anion radical (02j, yielding
peroxynitrite (OONO-). OONO- is a
potent oxidant that can decay under acidic
conditions to produce a powerfil hydoxyl-
like free radical (13). This reaction
between *NO and 02 can have a protec-
tive or damaging consequence, depending
on the individual sites and rates ofproduc-
tion ofthe free radicals, and the redox sta-
tus ofboth the generating cells as well as
the target cells. OONO- formation can
initiate adverse effects such as lipid peroxi-
dation ofmembranes, and modification of
structural proteins through nitration of
tyrosine residues (14). Indeed, increased
levels of3-nitrotyrosine have been detected
in the lungs ofpatients with sepsis and ani-
mals with acute lung injury. However,
OONO- can also S-nitrosylate glutathione
and other thiol-containing substances to
form S-nitrosothiols, which have marked
cardioprotective and cytoprotective
effects (15).
In vivo, substantial data, in both
animals and patients, have shown enhanced
*NO formation in sepsis. In rats, LPS
administration produced widespread iNOS
expression in various tissues, including the
vessel wall, with attenuation ofvascular
responsiveness. In a porcine model of
sepsis, endotoxin-induced hypotension was
reversed by the NOS inhibitor, nitro-
L-arginine methyl ester (L-NAME) (16).
In surgical patients with documented
sepsis, high levels ofnitrite and nitrate, the
metabolic end products of NO, correlated
with endotoxin levels and low systemic vas-
cular resistance (17); furthermore, in
patients with advanced cancer receiving
immunotherapy, a marked elevation in
serum nitrate levels was observed after IL-2
administration, which corresponded with
toxic hemodynamic changes (18).
Therapeutic Implications
Induction of iNOS within the vascular
wall, both in smooth muscle cells and
the endothelium, has been implicated in
the characteristic circulatory changes seen
in sepsis. The resulting increase in *NO
production can have profound effects on
hemodynamic stability by inducing vaso-
relaxation, which leads to a decrease in sys-
temic vascular resistance and hypotension.
This has led to numerous experimental
and clinical studies investigating the inhi-
bition of NO synthesis to restore arterial
blood pressure in sepsis (19). However,
given the complex physiologic effects of
*NO, including the potentially beneficial
nature of iNOS expression on tissue per-
fusion, cytoprotection, and immunoregu-
lation, the results of these studies have
been mixed.
The majority of these investigations
have achieved *NO inhibition using
L-arginine analogs. Numerous L-arginine
analogs, which act by competitively
inhibiting NOS, have been used to unravel
the functions of NO as well as potential
therapeutic agents. The majority of these
analogs act in a nonspecific manner, that
is, inhibition of both constitutive and
inducible isoforms, with different inhibi-
tors varying in potency with regard to
different isoforms (19). Despite improve-
ments in systemic blood pressure with
NOS inhibitors, the majority of clinical
reports published have shown adverse
effects on cardiac output and impaired
oxygen delivery (19,20). Experimental
studies using NOS inhibitors have also
revealed ambivalent findings. Although sev-
eral reports in animal models ofsepsis have
demonstrated an improvement in blood
pressure, blocking NOS activity decreases
renal blood flow, increases capillary leak
and intestinal damage, and exacerbates
pulmonaryhypertension (21,22).
The liver has long been recognized as
having an important role in the hemody-
namic, metabolic, and inflammatory
responses to sepsis. Systemic blockade of
*NO synthesis worsens hepatic injury in
endotoxemia (23). We have previously
demonstrated that this damaging effect of
NOS inhibition was, in part, mediated by
oxygen radicals and platelet deposition,
suggesting a cytoprotective role of NO in
preventing microvascular thrombosis and
as a free radical scavenger (24). In addi-
tion, 'NO has a protective role in hepatic
microcirculatory dysfunction during sepsis
through its effect on leukocyte adherence
to sinusoidal walls (25). Furthermore,
'NO may also protect against circulatory
vasoconstrictors during inflammation,
as enhanced 'NO synthesis counteracted
phenylephrine-induced increases in intra-
hepatic resistance in endotoxin-treated
rats (26). Finally, we have recentlydemon-
strated that different types of NOS
inhibitors resulted in detectable apoptosis
in the liver following LPS injection (27).
This increase in apoptosis was present even
with L-N-iminoethyl-lysine (L-NIL), a
rather specific inhibitor ofiNOS, revealing
another important protective role of NO
as an antiapoptotic agent in sepsis.
These seemingly divergent results with
NOS inhibitors suggest that although
overproduction of *NO in the vasculature
contributes to the vasodilatation seen in
septic shock, iNOS expression during
inflammation also represents a beneficial,
adaptive response in some organ systems.
Moreover, different tissues can react dis-
similarly to the effects of 'NO cytotoxic-
ity. In this setting, global nonselective
inhibition of NOS, including the poten-
tially undesirable consequences of eNOS
inhibition, would be harmful. If con-
firmed, this would suggest that use of
isoform-specific inhibitors ofNOS within
the vascular bed would be more appropri-
ate. Moreover, thorough pharmacokinetic
studies of these agents are warranted to
ensure their safe and effective use. A recent
study reported that S-methyl-isothiourea,
a relatively selective inhibitor of iNOS
activity, decreased pulmonary leak and
improved survival in endotoxemia (28).
However, because of the tissue-protective
and antiapoptotic effects of NO, even
selective iNOS inhibitors may be detri-
mental in certain tissues during sepsis. In
the future, combining the salutary effects
ofsite-specific local donors that exploit the
cytoprotective actions of 'NO with spe-
cific agents that combat the deleterious
hypotensive and tissue-damaging effects of
'NO overproduction may be needed to
treat septic shock (10). In this regard,
inhaled 'NO gas has shown promise as a
selective pulmonary vasodilator in patients
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with pulmonary hypertension associated
with sepsis (29). Any *NO gas reaching
the bloodstream is quickly inactivated by
binding to hemoglobin, thereby limiting
adverse dilatory effects in the systemic cir-
culation. Furthermore, we have recently
reported the efficacy of a liver-selective
NO prodrug in blocking TNF-a-induced
apoptosis and toxicity in the liver with lit-
tle effect on systemic blood pressure (30).
This prodrug is selectively metabolized to
biologically active *NO in hepatocytes
only, resulting in elevation of hepatic
cGMP levels.
Another approach to reducing 'NO
bioavailability may be the use of NO
scavengers. By impeding the reaction
between *NO and reactive oxygen species,
'NO scavengers may reduce the tissue-
damaging consequences of free radical
formation without overinhibition of
eNOS or iNOS. There has been consider-
able interest recently in the use ofcell-free
hemoglobin in septic shock. The pressor
response seen with cell-free hemoglobin
has been attributed to 'NO scavenging by
the heme (31).
Role of NO in Hemorrhagic
Shock
Physiologic studies ofhemorrhagic shock
(HS) have shown that in the face of
severe, prolonged hypovolemia, the neu-
roendocrine responses characteristic of
compensated shock begin to fail and a
decompensated state develops (32). This
decompensatory phase is characterized by
peripheral vasodilatation, capillary leak,
and hyporeactivity to pressor agents (33).
Recent studies have focused on 'NO as a
possible mediator ofdecompensation, with
increases in iNOS activity being reported
in several organs after prolonged hemor-
rhagic shock (34). In addition, inhibition
of *NO formation after hemorrhage not
only increased arterial pressure but also
improved renal blood flow, glomerular
filtration rate, and short-term survival
(35,36). This has led to speculation that
'NO production has a harmful effect
during HS and that NOS inhibitors may
provide therapeutic benefit. However,
there is conflicting evidence suggesting
'NO synthesis has a protective function.
Nonspecific 'NO blockade increased
shock-induced hepatic injury, an effect that
was reversible with L-arginine (37). A
recently published study reports that the
presence ofan NOS inhibitor, L-NAME,
during resuscitation from hemorrhage
prevented the restoration ofhepatic arterial
blood flow, suggesting a role for 'NO-
mediated vasodilatation in preventing
hepatic ischemia during HS (38). In
addition, the administration of 'NO
donors has been beneficial in models of
traumatic shock, hemorrhagic shock, and
mesenteric ischemia-reperfusion injury
(39). These latter studies suggest dimin-
ished *NO production occurs with hemor-
rhage. These findings are consistent with
those in trauma patients, where nitrite and
nitrate levels were reduced for prolonged
periods after injury (17,40). This impair-
ment of 'NO production in victims of
hemorrhagic hypotension may be due to
impairment ofeNOS, and indeed, several
investigators have demonstrated decreased
vasodilatory activity in vascular rings taken
from hemorrhaged animals in response to
agonists that stimulate endothelial 'NO
production (41). Furthermore, we recently
showed that vascular decompensation is
not due to excessive 'NO production by
the induced enzyme (42). Rats subjected
to HS were observed as they progressed
from compensated shock to decompen-
sated shock and ultimately irreversibility.
No iNOS expression could be detected
until the very late irreversible phase ofHS.
The hemodynamic instability associated
with decompensation occurred well before
NOS induction, indicating other factors or
vasoactive mediators must be involved in
decompensation (42).
The role of iNOS activity in HS
remains unclear, but recent studies suggest
that iNOS upregulation plays an impor-
tant role in the inflammatory response
that occurs in sustained HS followed by
resuscitation. Using either the selective
inhibitor L-NIL or iNOS knockout mice,
we found that iNOS inhibition or defi-
ciency not only prevented the upregula-
tion of the inflammatory cytokines IL-6
and granulocyte colony-stimulating fac-
tor following resuscitation from HS but
also produced a marked reduction in
lung and liver injury (43). Furthermore,
the activation of the proinflammatory
transcriptional factors nuclear factor
kappa B and signal transducer and activa-
tor of transcription 3 was also reduced,
suggesting iNOS upregulation has a key
role in proinflammatory signaling and the
subsequent activation of inflammatory
cascades. Though the basis of such a
'NO-signaling pathway needs further
clarification, several recent studies have
implicated a possible redox-sensitive mech-
anism. 'NO activates the critical signaling
enzyme p21ras through S-nitrosylation.
This activation is enhanced by depletion
of glutathione, the major antioxidant
present in cells (44). In HS, tissues are
subject to redox stress by hypoxia and
oxygen radical formation, suggesting this
'NO-p21ras interaction may be an impor-
tant cell-signaling mechanism in HS
and resuscitation.
Therapeutic Implications
Just as in sepsis, these apparently discrepant
findings would suggest that indiscriminate
use ofnonselective NOS inhibitors as an
adjuvant therapy in the treatment ofHS is
harmful. Although NOS inhibition has
improved hemodynamics in several models
ofHS (35,36), various examples oforgan
dysfunction have also been seen with their
use (37,38). It may be that better under-
standing and characterization of the
pharmacokinetics and selectivity ofNOS
inhibitors is needed prior to their use in
HS. As an example, a recent study showed
that although N-monomethyl-L-arginine
(L-NMMA), a nonselective inhibitor of
NOS, resulted in improved blood pressure
in rats subjected to hemorrhagic insult,
high-dose L-NMMA caused a marked
reduction in cardiac output and stroke vol-
ume, with increased damage in various
organs-deleterious effects that were
avoided with low-dose L-NMMA adminis-
tration (45). Furthermore, in rats subjected
to HS, L-NIL-based resuscitation reduced
liver damage compared to nonselective
NOS inhibitors (46).
Vascular quenching of 'NO using
scavengers mayagain provide an alternative
to NOS inhibition as a means to achieve
the goal of reducing 'NO levels. Use of
'NO scavengers after HS and resuscitation
may serve to supplement a possibly dep-
leted antioxidant defense system and limit
the harmful effects offree radicals such as
OONO-and hydoxyl radicals. Removal of
'NO by this method is complicated by the
extreme rapidity of the reaction between
'NO and 02'- (47). We have seen prom-
ising preliminary results with use of an
iron-based 'NO scavenger. In rats sub-
jected to HS, 'NO scavenger-based resusci-
tation improved liver injury and short-term
survival compared to standard volume
resuscitation (46).
Conclusion
In this review the emerging importance of
'NO and iNOS expression in the patho-
physiology ofcirculatory shock has been
examined. Although overproduction of
'NO may play a role in the hemodynamic
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changes seen in both septic shock and
hemorrhagic shock, iNOS upregulation
dearly also has a beneficial protective role in
several organ systems. In conditions where
excess NO production results in maladap-
tive damaging consequences with disrup-
tion ofhomeostasis, the therapeutic strategy
should be to remove this surplus 'NO
without adversely affecting the cytoprotec-
tive actions of *NO. Clearly, interfering
with the physiologic and microcirculatory
role ofeNOS through nonselective, global
inhibition of NOS is undesirable in
shock (Table 1). Though considerable
progress has been made over the last
decade, further improving our understand-
ing of the pathophysiology involved in
these processes and learning more about
the complex and diverse actions of 'NO
will help in developing more coherent,
efficacious therapeutic interventions.
Table 1. Effects of nitric oxide in endotoxemia and hemorrhagic shock and proposed therapeutic strategies for
manipulation of nitric oxide production.
Endotoxemia Hemorrhagic shock
Effects of NO by
eNOS Beneficial-maintains perfusion; Beneficial-maintains perfusion;
cytoprotective cytoprotective
iNOS Beneficial andtoxic-depending on site Beneficial and toxic-can induce
of production and microenvironment tissue damage and promote
inflammation with sustained shock
Therapeutic strategy
Inhibition of eNOS Avoid Avoid
Inhibition of iNOS Possibly desirable-to reduce Probablydesirable-to limit
cytotoxicityand combat hypotension exaggerated inflammatory response
and development of multiple organ
dysfunction syndrome
NO scavengers Probablydesirable-quench extra- Probably desirable-quench extra-
cellular NOwithout inhibition of cellular NO without inhibition of
eNOS or iNOS; supplement antioxidant eNOS or iNOS; supplement
defenses antioxidant defenses
NO donors Possiblydesirable-site-specific donors Possiblydesirable-site-specific
without adverse systemic side effects; donorswithout adverse systemic
limited availability side effects; limited availability
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